A Lung Cancer Drug Nearly Doubled the Pause, Plus Tenstorrent's $1.5B | Tech Arcade Podcast

Oct 28, 2026 · News · Chips & hardware

A two-target cancer drug called iza-bren nearly doubled how long lung cancer stayed in check compared with chemo in a phase three trial, but it has not yet shown patients live longer. Then, Jim Keller's Tenstorrent raises $1.5 billion at a $6.2 billion valuation to sell open RISC-V AI chips as an alternative to Nvidia.

Full story: https://www.techarcade.io/a-two-target-cancer-drug-just-cut-lung-cancer-progression-risk-by-60/

Full story: https://www.techarcade.io/jim-keller-s-tenstorrent-just-raised-1-5-billion-to-take-on-nvidia-with-open-chips/

Sources

https://www.onclive.com/view/iza-bren-improves-pfs-vs-platinum-chemo-in-egfr-mutated-nsclc-after-third-generation-tki

https://www.biopharminternational.com/view/bms-systimmune-iza-bren-phase-3-pfs-data-egfr-nsclc

https://www.webull.com/news/15774794933969920

https://www.pharmalive.com/bms-inks-potential-8-4b-deal-for-systimmunes-adc-for-lung-breast-cancer/

https://kyodonewsprwire.jp/release/202610218369

https://siliconangle.com/2026/10/19/chip-legend-jim-kellers-tenstorrent-raises-1-5b-to-expand-its-open-compute-ecosystem/

https://betakit.com/ai-chipmaker-tenstorrent-closes-nearly-700-million-usd-series-d-at-2-6-billion-valuation/

Where sources differ: reports disagree on Tenstorrent's headquarters (Toronto vs Santa Clara), so the episode leaves it out. No figure used in the episode is in dispute.

More at https://www.techarcade.io

#techarcade #lungcancer #biotech #Tenstorrent #AIchips

Watch on YouTube ↗Subscribe

▶ More videos

Video library →